证券之星消息，12月12日，生物经济（970038）指数报收于2103.93点，涨0.81%，成交172.47亿元，换 手率1.13%。当日该指数成份股中，上涨的有27家，华大基因以3.86%的涨幅领涨，下跌的有20家，福 瑞股份以3.23%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： 近10日内生物经济（970038）指数成份股做了调整，新纳入了9只股票，剔除了9只股票。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流入合计1.38亿元，游资资金净流出合 计4.0亿元，散户资金净流入合计2.62亿元。成份股资金流向详情见下表： ...

海利生物12月12日公告，公司拟收购陕西瑞盛生物科技有限公司剩余41%股权，本次交易完成后，对瑞 盛生物的持股比例达到96%。本次交易构成关联交易，未构成重大资产重组。 ...

Core Viewpoint - The article discusses the strategic investment of Yan Jianya, a newly crowned billionaire from Shaanxi, who acquired an 8% stake in the A-share listed company Sanrenxing for 450 million yuan, marking a significant move in the capital market [5][12]. Group 1: Investment Details - Yan Jianya's acquisition of Sanrenxing is seen as a "bottom-fishing" strategy, as the company has faced declining performance, with revenue dropping from 5.65 billion yuan in 2022 to 4.21 billion yuan in 2024, and net profit falling from 740 million yuan to 120 million yuan during the same period [5][13]. - Following the transaction, the controlling shareholder's stake in Sanrenxing decreased from 53.88% to 45.88%, while Yan Jianya became the second-largest shareholder with over 5% ownership [12][13]. - The deal is characterized as an effort to optimize the company's equity structure and introduce a significant strategic investor, which is expected to enhance governance and market credibility for Sanrenxing [13][14]. Group 2: Strategic Implications - For Sanrenxing, Yan Jianya's involvement is anticipated to bring threefold value: governance improvement, resource synergy, and strategic empowerment, particularly in expanding into high-end manufacturing and military sectors [13][14]. - Yan Jianya's investment is also a strategic positioning move, as Sanrenxing's marketing network and data resources could synergize with his beauty and skincare business, Giant Biogene, enhancing brand building and market promotion [14][15]. - The collaboration between Yan Jianya and Sanrenxing has been developing over several years, with previous joint ventures and investments laying the groundwork for this deeper capital connection [15][16]. Group 3: Broader Context of Yan Jianya's Investments - Prior to the Sanrenxing investment, Yan Jianya's notable investment was the acquisition of a 100% stake in Siyi Industrial by Kid King, valued at 1.65 billion yuan, marking it as the largest personal care acquisition in China this year [18][19]. - Yan Jianya's family empire includes three listed companies: Giant Biogene, Triangle Defense, and Sanrenxing, showcasing a diversified portfolio across biotechnology, advanced manufacturing, and marketing services [24][25]. - The family's investment strategy emphasizes industrial synergy, with plans for further capital expansion and resource integration through their private equity platform, Sanyuan Capital, which focuses on aerospace, new materials, and advanced manufacturing [26][29].

云南锗业（002428）(002428.SZ)公告，公司董事会审议通过《关于对外投资设立控股子公司的议 案》，同意公司与昆明哈傈佤企业管理合伙企业(有限合伙)(简称"昆明哈傈佤")共同出资1000万元设立 控股子公司云南锗业生物科技有限公司(暂定名，简称"云锗生物")。云锗生物主要从事以有机锗为核心 的日化产品及其他有机锗相关应用产品的开发业务。 ...

导语 市场"垃圾时间"不垃圾：机构在蓄势，科技仍是底仓。 临近年底，A股市场进入机构调仓换股冲刺期。 近来，多家上市公司因回购、并购等事项披露最新前十大流通股股东情况，多位百亿基金经理的最新调 仓动向也随之曝光，但操作有所分化。如在半导体赛道，嘉实基金王贵重、永赢基金张海啸加仓普冉股 份，兴证全球基金谢治宇减仓纳芯微；医药板块中，汇添富基金张韡建仓热景生物、大成基金徐彦出手 普洛药业。 同时，各大机构仍在勤奋调研，以期寻找好的机会。近一个月机构共调研1343家上市公司，合计调研次 数超过2000次。第一财经梳理发现，电子、机械设备等科技制造板块成"必争之地"，立讯精密单场调研 吸引近400家机构扎堆。 在受访人士看来，年末市场处于修整蓄势以及寻找未来方向的阶段，AI仍是长期核心主线。中信保诚 基金投研人士对第一财经表示，尽管市场短期或受情绪与资金面扰动，但在盈利修复、流动性宽裕及产 业趋势推动下，中长期"慢牛"格局依然值得期待，投资主线或将从概念预期进一步转向基本面验证。 年末基金经理各有调仓 在AI算力需求爆发的产业背景下，存储芯片行业成为机构加仓的重点方向。普冉股份最新前十大流通 股股东持股情况显示，截至 ...

Core Insights - The article emphasizes the importance of industry research as a driving force for investment, particularly focusing on the investment landscape in the biopharmaceutical sectors of China and the United States [1]. Investment Overview - The article discusses the investment landscape in the biopharmaceutical sector, highlighting successful venture capital (VC) cases in the U.S., such as Moderna, Alnylam Pharmaceuticals, and Intuitive Surgical, showcasing their growth trajectories and market impacts [2][4][6][9][11]. Investment Data Comparison - U.S. biopharmaceutical investments peaked at approximately $60.2 billion in 2021 but have since declined, with projections indicating a drop to $14.2 billion by 2025, reflecting challenges such as IPO market freezes and high interest rates [14]. - In China, the investment structure has shifted, with a notable decrease in early-stage financing from 42.15% in 2023 to 31.12% in 2024, while mid-to-late stage financing has slightly increased [16]. Medical System Differences - The U.S. healthcare system is characterized by high medical costs, with commercial insurance playing a crucial role in covering expenses, while the Chinese system is more influenced by government-led initiatives [27][28][29]. - The U.S. healthcare expenditure reached $4.6 trillion in 2023, accounting for 16.7% of GDP, with private health insurance being the largest payer [29]. Investment Strategies and Trends - U.S. venture capital firms are increasingly taking on active roles in company creation and development, moving beyond traditional financial investment to become integral in strategic and operational aspects [23]. - The article notes a trend towards "base + fund" ecosystems, where real estate investment trusts (REITs) focus on life sciences, creating environments conducive to innovation and collaboration [24]. Recent Financing Cases - Recent financing cases in the U.S. biopharmaceutical sector include significant investments in companies like Pathos AI and Eikon Therapeutics, indicating a focus on advanced technologies and clinical applications [25]. Comparative Analysis of LP Structures - The article contrasts the limited partner (LP) structures in the U.S. and China, noting that U.S. LPs are primarily composed of private capital seeking financial returns, while Chinese LPs are often government-led, focusing on strategic industry development [49][50].

天眼查App显示，近日，甘肃中禾优粮生物科技有限公司成立，法定代表人为王延利，注册资本200万 人民币，经营范围为许可项目：农作物种子经营（依法须经批准的项目，经相关部门批准后方可开展经 营活动）一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；生物饲料研 发；农林废物资源化无害化利用技术研发；饲料原料销售；谷物销售；农作物收割服务；天然草原割 草；初级农产品收购；农作物秸秆处理及加工利用服务；草及相关制品销售；饲料添加剂销售；农副产 品销售；畜牧渔业饲料销售；畜禽收购；畜禽粪污处理利用；牲畜销售；农林牧渔业废弃物综合利用； 农作物种子经营（仅限不再分装的包装种子）（除许可业务外，可自主依法经营法律法规非禁止或限制 的项目）。 ...

Core Insights - The article highlights the annual selection of the "Top Ten Advances in Life Sciences in China" by the Chinese Association for Science and Technology, showcasing significant innovations in the field aimed at enhancing public health and addressing critical issues in life sciences [2][36]. Group 1: Innovations in Cancer Treatment - A new strategy for enhancing and reducing toxicity in nasopharyngeal cancer immunotherapy has been developed, demonstrating a 44% reduction in failure risk and an increase in survival rate from 77.3% to 86.9% through the use of PD-1 monoclonal antibodies [4]. - The research also led to a decrease in chemotherapy-induced vomiting rates from 59.8% to 26.2% and reduced severe radiation therapy side effects from 33.2% to 21.6% [4]. Group 2: Caloric Restriction and Longevity - Research from Xiamen University identified a molecule called taurocholic acid that significantly increases in serum after caloric restriction, promoting health and longevity across various animal models [7]. - The study revealed that taurocholic acid activates the TULP3 receptor, which in turn activates Sirtuins, linking to the AMPK pathway, thus providing a theoretical basis for developing interventions that mimic caloric restriction effects [9]. Group 3: Neuroregeneration in Stroke Treatment - A novel "brain repair gel" developed by a collaborative team aims to improve the microenvironment post-stroke, promoting the regeneration of neurons and restoring sensory-motor functions [11]. - This approach marks a paradigm shift from passive protection to active regeneration in stroke treatment, with ongoing clinical trials validating its safety and efficacy [13]. Group 4: Metabolite Diversity and Disease Intervention - A team from Peking University discovered new gut microbiota-derived metabolites that regulate metabolic diseases, identifying orphan receptors as new targets for intervention [15]. - The research utilized AI to uncover specific synthetic enzymes, leading to the development of targeted intervention strategies for metabolic disorders [15]. Group 5: Advances in Genetic Engineering - The Chinese Academy of Sciences has developed an AI-driven protein engineering method that enables large-scale precise editing of DNA, which could revolutionize genetic disease treatment and crop breeding [24]. - This breakthrough represents a significant advancement in the application of AI in life sciences, showcasing the potential for deep learning to address biological challenges [24]. Group 6: Aging Interventions - Research teams have created a "protein scale" to quantify organ aging and identified key mechanisms driving aging, including the role of betaine as a "exercise mimetic" that slows multi-organ aging [26]. - The study also developed engineered anti-aging stem cells that can provide systemic protection against inflammation, contributing to the advancement of precision medicine in aging research [26]. Group 7: Insect Pheromone Research - A comprehensive analysis of locust aggregation pheromones has been conducted, leading to the development of specific inhibitors that can effectively control locust behavior [19]. - This research provides a foundational understanding for developing precise pest control strategies, marking a significant achievement in the field of entomology [19]. Group 8: Deep-Sea Evolutionary Mechanisms - A collaborative study has decoded the evolutionary processes of deep-sea animals, revealing how they adapt to extreme environments and providing insights into biodiversity [34]. - The findings challenge previous notions about deep-sea evolution, highlighting it as a site of innovation rather than a terminus for life [34].

0:00 暗室中 一株向日葵叶片舒展 花瓣泛起柔和荧光 这是合肥神笔生物科技有限公司 合肥神笔生物科技有限公司实验室最新研发的发光植物根系图。新华社发（受访企业供图） "神笔生物" 取自《神笔马良》的童话故事 承载着"以科技绘就未来"的初心 2024年 该公司成功培育出 每日上演的"魔法时刻" 12月3日，合肥神笔生物科技有限公司研发生产的能够在暗环境下自主持续发光的向日葵。新华社记者 张端 摄 基因编辑高亮度夜晚自发光植物 不仅填补了国内该领域的技术空白 更在国际舞台上 展现了中国企业的创新力量 12月3日，在合肥神笔生物科技有限公司实验室内，研发人员苗良杰在查看烟草生长情况。新华社记者 张端 摄 自成立以来 合肥神笔生物科技有限公司专注于 植物基因编辑与改良技术研发 研发团队由"95 后""00 后"组成 日，在合肥神笔生物科技有限公司实验室内，研发人员王朝慧在查看牵牛花组培苗的生长情况，这些组 培苗用于发光植物的研发。新华社记者 张端 摄 他们通过基因编辑技术 将萤火虫等生物的发光基因片段 导入植物细胞 让植物拥有了在暗环境下 自主持续发光的能力 日，在合肥神笔生物科技有限公司实验室内，研发人员刘笑准备 ...

格隆汇12月12日｜港股市场生物科技股走强，其中，昭衍新药涨超17%，加科思-B涨超8%，轩竹生物- B涨超7%，康方生物、圣诺医药-B涨超6%，基石药业-B涨超5%，同源康医药-B、云康集团、云顶新 耀、映恩生物-B涨超4%。 ...